(Q37866131)

24 August 2017

1 reference

title

Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach? (English)

1 reference

24 August 2017

author name string

Xavier Clemente-Casares

1

1 reference

24 August 2017

Sue Tsai

2

1 reference

24 August 2017

Yang Yang

3

1 reference

24 August 2017

Pere Santamaria

4

1 reference

24 August 2017

language of work or name

1 reference

16 April 2011

1 reference

Journal of Molecular Medicine

24 August 2017

published in

1 reference

24 August 2017

volume

89

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

733-742

1 reference

https://scigraph.springernature.com/pub.10.1007/s00109-011-0757-z

24 August 2017

exact match

0 references

cites work

T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Soluble MHC II-peptide complexes induce antigen-specific apoptosis in T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Functionally active recombinant alpha and beta chain-peptide complexes of human major histocompatibility class II molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Antigen-specific apoptosis in immortalized T cells by soluble MHC class II-peptide complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II:acetylcholine receptor peptide complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Regulation of encephalitogenic T cells with recombinant TCR ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Treatment of autoimmune anterior uveitis with recombinant TCR ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Recombinant T cell receptor ligand treats experimental stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Dimerization of soluble major histocompatibility complex-peptide complexes is sufficient for activation of T cell hybridoma and induction of unresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Reversal of autoimmunity by boosting memory-like autoregulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

A single-chain class II MHC-IgG3 fusion protein inhibits autoimmune arthritis by induction of antigen-specific hyporesponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Anergy induction by dimeric TCR ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

A peptide-major histocompatibility complex II chimera favors survival of pancreatic beta-islets grafted in type 1 diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

A comprehensive guide to antibody and T-cell responses in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

CD8+ T cells in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Thymus-specific deletion of insulin induces autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

The long and winding road to understanding and conquering type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

In situ recognition of autoantigen as an essential gatekeeper in autoimmune CD8+ T cell inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Individual nonobese diabetic mice exhibit unique patterns of CD8+ T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Cross-priming of diabetogenic T cells dissociated from CTL-induced shedding of beta cell autoantigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

How the immune system achieves self-nonself discrimination during adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Progression of autoimmune diabetes driven by avidity maturation of a T-cell population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0757-Z

Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera

21 January 2018

1 reference

12 December 2020

Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial

1 reference

12 December 2020

The requirements for antigen multivalency in class I antigen recognition and triggering of primed precursor cytolytic T lymphocytes

1 reference

12 December 2020

Diverse patterns of unresponsiveness in an acetylcholine receptor-specific T-cell clone from a myasthenia gravis patient after engaging the T-cell receptor with three different ligands

1 reference

12 December 2020

The role of major histocompatibility molecules in antigen-specific immune responses

1 reference

12 December 2020

Reversal of type 1 diabetes by a new MHC II-peptide chimera: "Single-epitope-mediated suppression" to stabilize a polyclonal autoimmune T-cell process

1 reference

12 December 2020

Design, engineering and production of functional single-chain T cell receptor ligands

1 reference

12 December 2020

Soluble, dimeric HLA DR4-peptide chimeras: an approach for detection and immunoregulation of human type-1 diabetes

1 reference

12 December 2020

RTL therapy for multiple sclerosis: a Phase I clinical study.

1 reference

12 December 2020

Single-chain recombinant HLA-DQ2.5/peptide molecules block α2-gliadin-specific pathogenic CD4+ T-cell proliferation and attenuate production of inflammatory cytokines: a potential therapy for celiac disease

1 reference

12 December 2020

Antigen-specific blockade of T cells in vivo using dimeric MHC peptide

1 reference

12 December 2020

An in vitro model for disease-specific immunotherapy in myasthenia gravis using soluble MHC class II bound to AChR-derived peptide

1 reference

12 December 2020

Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice

1 reference

12 December 2020

Two-domain MHC class II molecules form stable complexes with myelin basic protein 69-89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis

1 reference

12 December 2020

10.1007/S00109-011-0757-Z

Identifiers

DOI

1 reference

24 August 2017

1 reference